Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Agilent's AATI Acquisition To Strengthen Portfolio, Footprint

Published 03/07/2018, 09:43 PM
Updated 07/09/2023, 06:31 AM

Agilent Technologies, Inc. (NYSE:A) entered into a definitive agreement to acquire privately held Advanced Analytical Technologies (“AATI”) for $250 million.

Ankeny, IA-based, AATI is a developer of automated nucleic acid analysis systems using capillary electrophoresis methods. The company provides workflow solutions that include instruments, software and consumables. The solutions are extensively used for medical and molecular diagnostics for both commercial and research purposes.

The deal will strengthen Agilent’s capillary electrophoresis solutions portfolio. It also expands the company’s footprint in varied industries like pharmaceutical, life sciences, agriculture and biofuels.

Agilent shares closed at $69.70 on Mar 7, up 2.3%.

Acquisitions — Key Catalyst

Over the past few years, strategic acquisitions have played an important role in shaping Agilent’s growth trajectory. The buyouts of Multiplicom NV (January 2017), Cobalt Light Systems (July 2017), Seahorse Bioscience and iLab Solutions (2016) has expanded its product portfolio.

Multiplicom deal expanded Agilent’s genetic testing technology and product offerings. The Cobalt deal strengthened the company’s presence in the high-growth Raman spectroscopy market. The iLab Solutions acquisition enabled the company to provide cloud-based laboratory management software.

Moreover, Seahorse Bioscience’s technology was a strategic fit for Agilent’s market-leading separations and mass spectrometry solutions, especially those that cater to metabolomics and disease research in pharma.

In the last quarter, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-readers based in-vitro cell assay kits. The technology targets important applications, namely cell metabolism, bioenergetics, drug toxicity, and hypoxia and oxidative stress. The acquisition expands Agilent’s presence in the high-growth cell analysis market.

Zacks Rank & Stocks to Consider

Currently, Agilent carries a Zacks Rank #3 (Hold).

Investors interested in the broader technology sector can consider Teradyne (NYSE:TER) , AMETEK (NYSE:A) and Fortive Corporation (NYSE:FTV) . While Teradyne sports a Zacks Rank #1 (Strong Buy), AMETEK and Fortive carry a Zacks Rank #2 (Buy), each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term earnings growth rate for Teradyne, AMETEK and Fortive are currently pegged at 12%, 11.5% and 9.69%, respectively.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Agilent Technologies, Inc. (A): Free Stock Analysis Report

AMETEK, Inc. (AME): Free Stock Analysis Report

Teradyne, Inc. (TER): Free Stock Analysis Report

Fortive Corporation (FTV): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.